Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMMar 2026
$0+100.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Income Tax Expense vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.0% is the 3rd highest of 6, against a peer median of -81.0%.
  • Income tax expense amounts to 0.0% of revenue for ARCT, versus a peer median of 0.3%.
ARCT Competitors
Income Tax Expense for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVAXNovavax, Inc.LTM Mar 2026$1.65M USD-83.2%-24.3%0.3%
VALNValneva SELTM Mar 2026€423K EUR-81.0%—0.3%
VIRVir Biotechnology, Inc.LTM Mar 2026$371K USD+126.4%-90.3%0.6%
PRQRProQR Therapeutics N.V.LTM Mar 2026€18.99K EUR+109.5%-42.5%0.1%
SLNSilence Therapeutics plcLTM Mar 2026$14.71K USD—-73.0%1.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 USD+100.0%—0.0%
ABUSArbutus Biopharma CorporationLTM Mar 2026$0 USD——0.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026$0 USD———
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$6.32M USD-804.0%——
Peer median (excluding ARCT) —-81.0%-57.8%0.3%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.